These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 18769114)
1. Potential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma. Kast RE Cancer Biol Ther; 2008 Oct; 7(10):1515-9. PubMed ID: 18769114 [TBL] [Abstract][Full Text] [Related]
2. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993). Dutcher JP; Lee S; Gallagher RE; Makary AZ; Hines JD; Londer H; Farnen JP; Bennett JM; Paietta E; Rowe JM; Goloubeva O; Wiernik PH; Leuk Lymphoma; 2005 Mar; 46(3):377-85. PubMed ID: 15621827 [TBL] [Abstract][Full Text] [Related]
4. Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase. Russo D; Marin L; Bertone A; Tiribelli M; Testoni N; Martinelli G Haematologica; 1999 Feb; 84(2):185-7. PubMed ID: 10091422 [No Abstract] [Full Text] [Related]
5. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. Boorjian SA; Milowsky MI; Kaplan J; Albert M; Cobham MV; Coll DM; Mongan NP; Shelton G; Petrylak D; Gudas LJ; Nanus DM J Immunother; 2007 Sep; 30(6):655-62. PubMed ID: 17667529 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma. Escudier B; Ravaud A; Berton D; Chevreau C; Douillard JY; Dietrich PY J Immunother; 1998 Jan; 21(1):62-4. PubMed ID: 9456438 [TBL] [Abstract][Full Text] [Related]
8. Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia. Egyed M; Kollár B; Rumi G; Keller E; Vass J; Fekete S Acta Haematol; 2003; 109(2):84-9. PubMed ID: 12624492 [TBL] [Abstract][Full Text] [Related]
9. [Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon]. Egyed M; Mihályfalvi Z; Kollár B; Rumi G; Keller E; Vass J; Fekete S Orv Hetil; 2001 Nov; 142(44):2421-5. PubMed ID: 11766235 [TBL] [Abstract][Full Text] [Related]
10. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients. Toma S; Raffo P; Nicolo G; Canavese G; Margallo E; Vecchio C; Dastoli G; Iacona I; Regazzi-Bonora M Int J Oncol; 2000 Nov; 17(5):991-1000. PubMed ID: 11029503 [TBL] [Abstract][Full Text] [Related]
12. Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM. Marley SB; Davidson RJ; Goldman JM; Gordon MY Leukemia; 2000 Aug; 14(8):1396-400. PubMed ID: 10942234 [TBL] [Abstract][Full Text] [Related]